A nationwide recall of popular weight loss injections has been issued after federal regulators determined the manufacturer could not guarantee the drugs were sterile, potentially exposing thousands of patients to serious infection risks.
Recall Affects 23 Vials of Injectable Medications
Apothecary Pharma voluntarily pulled 23 vials of injectable drugs from distribution across the country, the Food and Drug Administration announced. The recall includes 22 vials of compounded tirzepatide, which contains the same active ingredient found in Eli Lilly’s brand-name weight loss medications Mounjaro and Zepbound, plus one vial of NAD+ injection. The FDA classified this as a Class II recall on October 8, meaning serious health consequences are unlikely but possible.
The affected tirzepatide product is an 18 mg/mL prescription injection packaged in 4 mL multidose vials. Recalled lot numbers range from AP-202622 through AP-202644, with expiration dates spanning October 7 through November 26, 2026. The NAD+ injection recall involves a 200 mg/mL prescription product in 6 mL vials, lot number AP-202647, expiring October 13, 2026.
Prior FDA Warning Cited Production Problems
The North Carolina-based company received an FDA warning letter in December 2025 documenting serious deficiencies in its sterile drug production practices. Federal inspectors determined these problems created patient safety risks, though the agency has not directly linked those earlier findings to the current recall. Apothecary Pharma initiated the withdrawal on September 24 and began notifying customers by letter. The recall remains active as officials work to remove all affected products from circulation.
What Patients Should Do Now
Consumers who have purchased these medications should immediately check their vial labels or pharmacy records against the recalled lot numbers. Anyone with affected products should stop using them right away and contact their pharmacist or prescribing doctor for replacement options. Patients who develop fever, redness, swelling or worsening pain at injection sites after using these products should seek medical attention promptly. The FDA has not received reports of illnesses or injuries connected to the recalled vials, but officials urge vigilance given the sterility concerns that prompted the withdrawal.